Keepers GA, Fochtmann LJ, Anzia JM, Benjamin S, Lyness JM, Mojtabai R, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2020;177:868–72.

PubMed  Google Scholar 

Barnes TR, Drake R, Paton C, Cooper SJ, Deakin B, Ferrier IN, et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2020;34:3–78.

PubMed  Google Scholar 

Correll CU, Kane JM. Ranking antipsychotics for efficacy and safety in schizophrenia. JAMA Psychiatry. 2020;77:225–6.

PubMed  Google Scholar 

Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394:939–51.

CAS  PubMed  PubMed Central  Google Scholar 

Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, Tagashira R, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther. 2010;334:171–81.

CAS  PubMed  Google Scholar 

Meltzer HY, Matsubara S, Lee J. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther. 1989;251:238–46.

CAS  PubMed  Google Scholar 

Fiorillo A, Cuomo A, Sampogna G, Albert U, Calò P, Cerveri G, et al. Lurasidone in adolescents and adults with schizophrenia: from clinical trials to real-world clinical practice. Expert Opin Pharmacother. 2022;23:1801–18.

CAS  PubMed  Google Scholar 

Leucht S, Leucht C, Huhn M, Chaimani A, Mavridis D, Helfer B, et al. Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors. Am J Psychiatry. 2017;174:927–42.

PubMed  Google Scholar 

Chen AT, Nasrallah HA. Neuroprotective effects of the second generation antipsychotics. Schizophr Res. 2019;208:1–7.

CAS  PubMed  Google Scholar 

Meltzer HY, Share DB, Jayathilake K, Salomon RM, Lee MA. Lurasidone improves psychopathology and cognition in treatment-resistant schizophrenia. J Clin Psychopharmacol. 2020;40:240.

CAS  PubMed  PubMed Central  Google Scholar 

Thomas P, Alptekin K, Gheorghe M, Mauri M, Olivares JM, Riedel M. Management of patients presenting with acute psychotic episodes of schizophrenia. CNS Drugs. 2009;23:193–212.

CAS  PubMed  Google Scholar 

Samara MT, Leucht C, Leeflang MM, Anghelescu I-G, Chung Y-C, Crespo-Facorro B, et al. Early improvement as a predictor of later response to antipsychotics in schizophrenia: a diagnostic test review. Am J Psychiatry. 2015;172:617–29.

PubMed  Google Scholar 

Kishi T, Nakamura H, Iwata N. Early improvement as a predictor of later response to lurasidone in schizophrenia from Japan trials: a diagnostic test. Psychiatry Clin Neurosci. 2022;76:401–2.

PubMed  Google Scholar 

Ruderfer DM, Charney AW, Readhead B, Kidd BA, Kähler AK, Kenny PJ, et al. Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach. Lancet Psychiatry. 2016;3:350–7.

PubMed  PubMed Central  Google Scholar 

Li J, Yoshikawa A, Brennan MD, Ramsey TL, Meltzer HY. Genetic predictors of antipsychotic response to lurasidone identified in a genome wide association study and by schizophrenia risk genes. Schizophr Res. 2017.

Li J, Loebel A, Meltzer HY. Identifying the genetic risk factors for treatment response to lurasidone by genome-wide association study: a meta-analysis of samples from three independent clinical trials. Schizophr Res. 2018;199:203–13.

PubMed  Google Scholar 

Meltzer HY, Cucchiaro J, Silva R, Ogasa M, Phillips D, Xu J, et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo-and olanzapine-controlled study. Am J Psychiatry. 2011;168:957–67.

PubMed  Google Scholar 

Nasrallah HA, Silva R, Phillips D, Cucchiaro J, Hsu J, Xu J, et al. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study. J Psychiatr Res. 2013;47:670–7.

PubMed  Google Scholar 

Loebel A, Cucchiaro J, Sarma K, Xu L, Hsu C, Kalali AH, et al. Efficacy and safety of lurasidone 80mg/day and 160mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo-and active-controlled trial. Schizophr Res. 2013;145:101–9.

PubMed  Google Scholar 

Purcell S, Chang C PLINK 1.9. URL https://www.cog-genomics.org/plink2 2015.

Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81:559–75.

CAS  PubMed  PubMed Central  Google Scholar 

Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet. 2006;38:904–9.

CAS  PubMed  Google Scholar 

de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set analysis of GWAS data. PLoS Comput Biol. 2015;11:e1004219.

PubMed  PubMed Central  Google Scholar 

Gauderman WJ. Sample size requirements for association studies of gene-gene interaction. Am J Epidemiol. 2002;155:478–84.

PubMed  Google Scholar 

Singh T, Poterba T, Curtis D, Akil H, Al Eissa M, Barchas JD, et al. Rare coding variants in ten genes confer substantial risk for schizophrenia. Nature. 2022;604:509–16.

CAS  PubMed  PubMed Central  Google Scholar 

Luoni A, Richetto J, Longo L, Riva M. Chronic lurasidone treatment normalizes GABAergic marker alterations in the dorsal hippocampus of mice exposed to prenatal immune activation. Eur Neuropsychopharmacol. 2017;27:170–9.

CAS  PubMed  Google Scholar 

Numakawa T, Odaka H, Adachi N. Actions of brain-derived neurotrophin factor in the neurogenesis and neuronal function, and its involvement in the pathophysiology of brain diseases. Int J Mol Sci. 2018;19:3650.

PubMed  PubMed Central  Google Scholar 

Jena M, Ranjan R, Mishra BR, Mishra A, Nath S, Sahu P, et al. Effect of lurasidone vs olanzapine on neurotrophic biomarkers in unmedicated schizophrenia: a randomized controlled trial. J Psychiatr Res. 2019;112:1–6.

PubMed  Google Scholar 

Delmotte Q, Diabira D, Belaidouni Y, Hamze M, Kochmann M, Montheil A, et al. Sonic hedgehog signaling agonist (SAG) triggers BDNF secretion and promotes the maturation of GABAergic networks in the postnatal Rat hippocampus. Front Cell Neurosci. 2020;14:98.

CAS  PubMed  PubMed Central  Google Scholar 

Hynes M, Porter JA, Chiang C, Chang D, Tessier-Lavigne M, Beachy PA, et al. Induction of midbrain dopaminergic neurons by Sonic hedgehog. Neuron. 1995;15:35–44.

CAS  PubMed  Google Scholar 

Jeong Y, Dolson DK, Waclaw RR, Matise MP, Sussel L, Campbell K, et al. Spatial and temporal requirements for sonic hedgehog in the regulation of thalamic interneuron identity. Development. 2011;138:531–41.

CAS  PubMed  PubMed Central  Google Scholar 

Martı́ E, Bovolenta P. Sonic hedgehog in CNS development: one signal, multiple outputs. Trends Neurosci. 2002;25:89–96.

PubMed  Google Scholar 

Pusapati GV, Kong JH, Patel BB, Gouti M, Sagner A, Sircar R, et al. G protein–coupled receptors control the sensitivity of cells to the morphogen Sonic Hedgehog. Sci Signal. 2018;11:eaao5749.

PubMed  PubMed Central  Google Scholar 

Lauth M, Rohnalter V, Bergström Å, Kooshesh M, Svenningsson P, Toftgård R. Antipsychotic drugs regulate hedgehog signaling by modulation of 7-dehydrocholesterol reductase levels. Mol Pharmacol. 2010;78:486–96.

CAS  PubMed  Google Scholar 

Brickley SG, Mody I. Extrasynaptic GABA A receptors: their function in the CNS and implications for disease. Neuron. 2012;73:23–34.

CAS  PubMed  PubMed Central  Google Scholar 

Rudolph U, Knoflach F. Beyond classical benzodiazepines: novel therapeutic potential of GABA A receptor subtypes. Nat Rev Drug Discov. 2011;10:685.

CAS  PubMed  PubMed Central  Google Scholar 

Möhler H. Molecular regulation of cognitive functions and developmental plasticity: impact of GABAA receptors. J Neurochem. 2007;102:1–12.

PubMed  Google Scholar 

Brickley SG, Mody I. Extrasynaptic GABAA receptors: their function in the CNS and implications for disease. Neuron. 2012;73:23–34.

CAS  PubMed  PubMed Central  Google Scholar 

Miyamoto S, Duncan G, Marx C, Lieberman J. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry. 2005;10:79.

CAS  PubMed  Google Scholar 

Rudolph U, Möhler H. GABAA receptor subtypes: therapeutic potential in Down syndrome, affective disorders, schizophrenia, and autism. Annu Rev Pharmacol Toxicol. 2014;54:483.